Essex Bio-Technology Limited operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Essex Bio-Technology Limited with three other
pharmaceutical manufacturers in Asia:
Walvax Biotechnology Company Limited
sales of 667.51 million Chinese Renmimbi [US$96.41 million]
of which 81%
was Production Segment),
Vcanbio Cell & Gene Engineering Corp Ltd
(868.97 million Chinese Renmimbi [US$125.51 million]
of which 72%
was Stem cell related business), and
Zhenxing Biopharmaceutical & Chemical Co Ltd
based in China
(685.38 million Chinese Renmimbi [US$98.99 million]
of which 99%
was Pharmaceutical Sales).
Essex Bio-Technology Limited reported sales of HK$899.59 million (US$114.79 million)
December of 2017.
increase of 16.0%
versus 2016, when the company's sales were HK$775.66 million.
Sales at Essex Bio-Technology Limited have increased during each of the previous five years
(and since 2012, sales have increased a total of 237%).
Sales of Sales of Pharmaceutical Products saw an increase
20.3% in 2017, from
HK$727.82 million to HK$875.20 million.
Not all segments of Essex Bio-Technology Limited experienced an increase in sales in 2017:
sales of Other Businesses fell 49.0% to HK$24.39 million.